Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trotabresib with Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma
NCT04324840Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Jul 2020
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, randomised, open-label trial of trotabresib in glioblastoma (GBM) (3 arms), sponsored by Celgene Corporation. Primary endpoints: Incidence of adverse events up to 3 years, Incidence of serious adverse events up to 3 years and 5 more. Started Jul 2020; status: terminated.
02
Drugs
trotabresib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04324840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04324840.